IN2014DN08158A - - Google Patents

Info

Publication number
IN2014DN08158A
IN2014DN08158A IN8158DEN2014A IN2014DN08158A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A IN 8158DEN2014 A IN8158DEN2014 A IN 8158DEN2014A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A
Authority
IN
India
Prior art keywords
disclosed
methods
function
specific inhibitor
smad7 expression
Prior art date
Application number
Inventor
Giovanni Monteleone
Peter Buchwald
Luca Inverardi
Antonello Pileggi
Camillo Ricordi
Alice Tomei
Original Assignee
Nogra Pharma Ltd
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd, Univ Miami filed Critical Nogra Pharma Ltd
Publication of IN2014DN08158A publication Critical patent/IN2014DN08158A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell e.g. pancreatic islet cell survival after transplantation using a specific inhibitor of SMAD7 expression or function.
IN8158DEN2014 2012-04-18 2013-04-18 IN2014DN08158A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (1)

Publication Number Publication Date
IN2014DN08158A true IN2014DN08158A (en) 2015-05-01

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8158DEN2014 IN2014DN08158A (en) 2012-04-18 2013-04-18

Country Status (14)

Country Link
US (3) US10081809B2 (en)
EP (1) EP2839004B1 (en)
JP (2) JP6348484B2 (en)
KR (1) KR20150003824A (en)
CN (2) CN107252492A (en)
AU (1) AU2013249191B2 (en)
CA (1) CA2870547A1 (en)
DK (1) DK2839004T3 (en)
ES (1) ES2732252T3 (en)
IN (1) IN2014DN08158A (en)
MX (1) MX370149B (en)
NZ (1) NZ630914A (en)
RU (1) RU2667960C2 (en)
WO (1) WO2013158868A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
MX346335B (en) 2008-11-13 2017-03-14 Nogra Pharma Ltd Antisense compositions and methods of making and using same.
EP2748611B1 (en) 2011-09-15 2016-11-23 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
IN2014DN08158A (en) 2012-04-18 2015-05-01 Nogra Pharma Ltd
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP2940115B1 (en) * 2014-04-30 2018-10-17 The Procter and Gamble Company Cleaning composition
US10473669B2 (en) 2014-05-09 2019-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
AU2015332624A1 (en) 2014-10-17 2017-05-04 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
ES2718380T3 (en) * 2015-10-29 2019-07-01 Procter & Gamble Liquid detergent composition
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHODS OF TREATING INTESTINAL FIBROSIS BY INHIBITING SMAD7
US11584935B2 (en) * 2018-05-08 2023-02-21 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
ES2388968T3 (en) 2001-11-02 2012-10-22 Giuliani International Limited Smad7 inhibitors for the treatment of CNS diseases
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
ES2905724T3 (en) * 2003-06-13 2022-04-11 Alnylam Europe Ag Double-stranded ribonucleic acid with high efficacy in an organism
ITRM20030393A1 (en) * 2003-08-11 2005-02-12 Giuliani Spa USE OF OLIGONUCLEOTIDES (ODN) ANTISENSE FOR SMAD7 FOR THE TREATMENT OF PATHOLOGIES MEDIATED BY NUCLEAR TRANSFER FACTOR NF-KB.
GB0326778D0 (en) 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
PT1799269T (en) 2004-09-28 2016-10-04 Quark Pharmaceuticals Inc Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
RU2434942C2 (en) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Oligiribonucleotides and methods of their application for treatment of acute renal failure and other diseases
WO2007039151A1 (en) 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
ES2554168T3 (en) * 2008-04-18 2015-12-16 Baxter International Inc. Microsphere-based composition to prevent and / or reverse newly occurring autoimmune diabetes
MX346335B (en) 2008-11-13 2017-03-14 Nogra Pharma Ltd Antisense compositions and methods of making and using same.
EP2748611B1 (en) 2011-09-15 2016-11-23 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
IN2014DN08158A (en) 2012-04-18 2015-05-01 Nogra Pharma Ltd
AU2014229985B2 (en) 2013-03-15 2018-12-13 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
US10473669B2 (en) 2014-05-09 2019-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2016059243A2 (en) 2014-10-17 2016-04-21 Nogra Pharma Limmited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
AU2015332624A1 (en) 2014-10-17 2017-05-04 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
WO2017055611A2 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
EP3420085A1 (en) 2016-02-24 2019-01-02 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
CA3048334A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
CA2870547A1 (en) 2013-10-24
MX370149B (en) 2019-12-03
JP2015514778A (en) 2015-05-21
US20200239884A1 (en) 2020-07-30
WO2013158868A1 (en) 2013-10-24
EP2839004A1 (en) 2015-02-25
MX2014012650A (en) 2015-04-08
CN107252492A (en) 2017-10-17
DK2839004T3 (en) 2019-07-01
US20190136237A1 (en) 2019-05-09
AU2013249191A1 (en) 2014-10-09
RU2014146170A (en) 2016-06-10
EP2839004B1 (en) 2019-06-12
NZ630914A (en) 2017-01-27
US10443056B2 (en) 2019-10-15
JP6348484B2 (en) 2018-06-27
CN104487574A (en) 2015-04-01
KR20150003824A (en) 2015-01-09
US20150315573A1 (en) 2015-11-05
US10081809B2 (en) 2018-09-25
ES2732252T3 (en) 2019-11-21
JP2018131468A (en) 2018-08-23
RU2667960C2 (en) 2018-09-25
AU2013249191B2 (en) 2019-01-03
CN104487574B (en) 2017-07-07
HK1207117A1 (en) 2016-01-22

Similar Documents

Publication Publication Date Title
IN2014DN08158A (en)
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
UA118328C2 (en) Targeted gemomic alteration
SG10201906304TA (en) Use of perfusion decellularized liver for islet cell recellularization
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX355728B (en) Kinase inhibitors.
MX371176B (en) Hollow fiber cartridges and components and methods of their construction
IL224451A (en) Method of producing pancreatic hormone-producing cells
PH12013500349A1 (en) Differentiation of pluripotent stem cells
PH12014500995A1 (en) Pak inhibitors for the treatment of cell proliferative disorders
PH12014502588A1 (en) Catechol o-methyltransferase activity inhibiting compounds
JO3450B1 (en) New modified release dosage forms of xanthine oxidoreductase inhibitors or xanthine oxidase inhibitors.
IN2014DN11201A (en)
MX2014013752A (en) Nampt inhibitors.
PH12014502513A1 (en) Nampt inhibitors
HK1218139A1 (en) Cell compositions derived from dedifferentiated reprogrammed cells
MX348311B (en) Nampt inhibitors.
IL240934A0 (en) Method of treating pancreatic and liver conditions by transplantation of stem cells into bile duct walls
MX2021000332A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor.
MX2013006165A (en) Controlled degradation fibers.
SG11201408717XA (en) Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
MX393754B (en) Methods and compositions for inhibiting cnksr1
IL237118A0 (en) Methods of isolating distinct pancreatic cell types
MX2010007945A (en) Pancreatic islet cell preparation and transplantation.
EA201590551A1 (en) METHODS OF INHIBITING GROWTH OF HAIR